Home

Cybin Inc. Common Shares (CYBN)

9.9100
-0.0700 (-0.70%)

Cybin Inc is a biotechnology company focused on developing innovative psychedelic-based therapeutic solutions to address various mental health disorders

The company is engaged in research and clinical development of psychedelic compounds, aiming to enhance mental health treatment options through advanced drug formulations and delivery methods. By leveraging the potential of psychedelics, Cybin strives to provide patients with new avenues for healing and improved quality of life, while also working to advance the understanding and acceptance of psychedelic therapies in mainstream medicine.

SummaryNewsPress ReleasesChartHistoricalFAQ
Is Your Mind Ready to Consider Investing in Psychedelics Stocks?fool.com
Don't jump in without doing some research first.
Via The Motley Fool · November 29, 2024
Cybin Inc. Begins Phase 3 Trials, Betting Big On CYB003 To Treat Depressionbenzinga.com
Cybin starts Phase 3 trials for its depression treatment, CYB003, backed by strong Phase 2 data and a solid cash position.
Via Benzinga · November 13, 2024
EXCLUSIVE: Neuropsychiatry-Focused Cybin Secures First US Composition of Matter Patent For Preclinical CYB005 Phenethylamines Programbenzinga.com
Cybin secures a U.S. patent for its CYB005 program targeting CNS disorders and prepares to launch a Phase 3 trial for CYB003 in major depressive disorder.
Via Benzinga · October 24, 2024
Leadership Shake-Ups In Cannabis And Psychedelics: Maryland's Cannabis Chief Resigns, Costly Legal Battle In MA Drags On & Morebenzinga.com
Maryland transitioned to an adult-use cannabis market a little over a year ago. Led by the state's Cannabis Administration Director, Will Tilburg, the transition resulted in the state's legal cannabis sales surpassing $1.1 billion in the first year following legalization. In August, Maryland Matters reported that Tilburg, who has spent six years working on the state's cannabis policy, announced his decision to step down from his current role on Dec.4, 2024.
Via Benzinga · September 6, 2024
CYBN Stock Earnings: Cybin Beats EPS for Q1 2024investorplace.com
CYBN stock results show that Cybin beat analyst estimates for earnings per share the first quarter of 2024.
Via InvestorPlace · August 9, 2024
CYBN Stock Earnings: Cybin Beats EPS for Q4 2023investorplace.com
CYBN stock results show that Cybin beat analyst estimates for earnings per share the fourth quarter of 2023.
Via InvestorPlace · June 26, 2024
Cybin Inc. Q3 Earnings: Clinical Advances Amid Financial Lossbenzinga.com
The TDR Three Key Takeaways:
Via Benzinga · February 16, 2024
EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelvesbenzinga.com
Jamaica introduces its first legal psilocybin products in pharmacies through a historic partnership between PATOO and Fontana Pharmacy.
Via Benzinga · July 31, 2024
3 Biotech Stocks That Could Make Your Summer Unforgettableinvestorplace.com
If you want to do well with biotech stocks, trade the anticipation of news. Here are three stocks to consider.
Via InvestorPlace · July 30, 2024
Psychedelic Picks: 3 Trippy Stocks Aiming for Out-of-This-World Returnsinvestorplace.com
Psychedelics could be a game-changer in treating mental health issues, creating substantial opportunities for top psychedelic stocks.
Via InvestorPlace · July 3, 2024
3 Psychedelic Stocks to Buy on the Dip: Summer 2024investorplace.com
These are three of the best psychedelic stocks to buy on the dip for potentially lucrative future growth and returns.
Via InvestorPlace · July 2, 2024
Biopharma Co. Cybin Reports $78M Loss Amid Accelerating Expansion In Psychedelic Therapies, Drug Developmentbenzinga.com
Explore Cybin Inc.'s FY 2024 results: $78M loss and strides in psychedelic therapy for mental health. Read now!
Via Benzinga · June 26, 2024
Latest Executive Cannabis Changes You Should Know About: Curaleaf, Planet 13 Elect Directors And Morebenzinga.com
As the premier gathering of top entrepreneurs and investors is taking place this Monday in New Jersey, let's scroll through the latest leadership changes in the cannabis and psychedelics industries.Cybin Inc.announced recently that Dr. Atul R. Mahableshwarkar M.D., DLFAPA, opted to join the company as senior vice president of clinical development. In addition, six cannabis companies announced changes to their respective boards of directors.
Via Benzinga · June 18, 2024
Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatmentbenzinga.com
FDA panel rejects MDMA therapy for PTSD, citing lack of evidence for benefits outweighing risks. Psychedelic stocks take a hit, with CYBN, MNMD, and ATAI down. FDA not bound by decision.
Via Benzinga · June 5, 2024
Pot Company Gets License To Open Psilocybin Service Center, The Sacred Mushroom, In Oregonpot-com
Via Benzinga · May 9, 2024
Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And Morebenzinga.com
Via Benzinga · March 30, 2024
3 Penny Stocks That Could Be Multibaggers in the Making: March Editioninvestorplace.com
Penny stocks are incredibly risky. However, if you can handle the heat, these ideas might be worth your while.
Via InvestorPlace · March 26, 2024
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And Morebenzinga.com
Via Benzinga · March 20, 2024
FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private Placementbenzinga.com
Via Benzinga · March 13, 2024
3 High-Potential Penny Stocks to Turn $1000 into $1 millioninvestorplace.com
U.S. equities are in the midst of a steady rally, but these high-potential penny stocks are likely to trounce the major indices.
Via InvestorPlace · March 10, 2024
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And Morebenzinga.com
Via Benzinga · March 4, 2024
Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And Morebenzinga.com
Via Benzinga · February 15, 2024
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And Morebenzinga.com
New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian psychiatrists provide first psychedelic-assisted treatments in 50 years.
Via Benzinga · January 27, 2024
FDA Green Lights Cybin's Psychedelic Clinical Study Assessing Generalized Anxietybenzinga.com
Cybin will advance the clinical development of the novel psychedelic molecule CYB004 for generalized anxiety treatment.
Via Benzinga · January 23, 2024
Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & Morebenzinga.com
Welcome to Benzinga's weekly psychedelics headlines roundup. This is our pick of must-read news items from the second week of January 2024. 
Via Benzinga · January 15, 2024